Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
DIN 01916882: Clavulin
Raw flags: sec3=Y
Item: 081216054; group id 26; item number 0048; lccId None; manufacturer id GSK
Source form: O/L; strength: 25mg & 6.25mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.1265; ministry $0.1265
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916882
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15208
Shortage status: resolved shortage (ended June 20, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01916882
DIN 01916874: Clavulin
Raw flags: sec3=Y
Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id GSK
Source form: O/L; strength: 50mg & 12.5mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.2753; ministry $0.1216
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916874
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15209Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539438 · $0.1216
M-Amoxi Clav · DIN 02542226 · $0.1216
Shortage status: resolved shortage (ended March 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01916874
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539438
Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27
Daily cost (source): $1.8240
Health Canada: Marketed since 2024-07-22 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML · company Jamp pharma corporation · schedule Prescription
Jamp Amoxi Clav Suspension: Formulary list price $0.12 per unit (the source does not state the unit; exact figure $0.1216). What the ministry pays, not the patient.
Ministry pays: $0.1216 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02539438: Jamp Amoxi Clav Suspension
Raw flags: sec3=Y
Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id JPC
Source form: O/L; strength: 50mg & 12.5mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.1216; ministry $0.1216
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539438
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102818Interchangeable products
Clavulin · DIN 01916874 · $0.1216
M-Amoxi Clav · DIN 02542226 · $0.1216
Shortage status: active shortage (reported March 12, 2026, estimated to end November 20, 2026, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539438
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amoxi Clav · DIN 02542226
Manufacturer: Mantra Pharma Inc.; listing date 2024-03-28
Daily cost (source): $1.8240
Health Canada: Marketed since 2024-02-01 · brand M-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML · company Mantra pharma inc · schedule Prescription
DIN 02542226: M-Amoxi Clav
Raw flags: sec3=Y
Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id MAT
Source form: O/L; strength: 50mg & 12.5mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.1216; ministry $0.1216
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02542226
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103081Interchangeable products
Clavulin · DIN 01916874 · $0.1216
Jamp Amoxi Clav Suspension · DIN 02539438 · $0.1216
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02542226
Shortage record checked October 6, 2026
Clavulin (BID) · DIN 02238831 · 200 mg & 28.5 mg/5 mL · suspension
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Clavulin (BID) · DIN 02238831
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17
Health Canada: Marketed since 2003-01-15 · brand CLAVULIN 200 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 200 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 28.5 MG/5ML · company Glaxosmithkline inc · schedule Prescription
DIN 02238831: Clavulin (BID)
Raw flags: sec3=Y
Item: 081216081; group id 26; item number 0050; lccId None; manufacturer id GSK
Source form: Susp; strength: 200mg & 28.5mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.1974; ministry $0.1007
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238831
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62269Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539411 · $0.1007
Shortage status: resolved shortage (ended June 2, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238831
Apo-Amoxi Clav: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2467). What the ministry pays, not the patient.
Ministry pays: $0.2467 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02243350: Apo-Amoxi Clav
Raw flags: sec3=Y
Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id APX
Source form: Tab; strength: 250mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.2467; ministry $0.2467
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243350
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67257Interchangeable products
Auro-Amoxiclav · DIN 02471671 · $0.2467
Clavulin · DIN 01916866 · not recorded
Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: shortage reported ended April 23, 2026 (report last updated April 23, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243350
Auro-Amoxiclav: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2467). What the ministry pays, not the patient.
Ministry pays: $0.2467 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02471671: Auro-Amoxiclav
Raw flags: sec3=Y
Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id AUR
Source form: Tab; strength: 250mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.2467; ministry $0.2467
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471671
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96090Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467
Clavulin · DIN 01916866 · not recorded
Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: resolved shortage (ended February 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471671
Jamp Amoxi Clav: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2467). What the ministry pays, not the patient.
Ministry pays: $0.2467 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02508249: Jamp Amoxi Clav
Raw flags: sec3=Y
Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id JPC
Source form: Tab; strength: 250mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.2467; ministry $0.2467
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508249
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99763Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467
Auro-Amoxiclav · DIN 02471671 · $0.2467
Clavulin · DIN 01916866 · not recorded
Shortage status: resolved shortage (ended April 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508249
Shortage record checked October 6, 2026
Clavulin (BID) · DIN 02238830 · 400 mg & 57 mg/5 mL · suspension
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Clavulin (BID) · DIN 02238830
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17
Health Canada: Marketed since 2002-12-17 · brand CLAVULIN 400 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML · company Glaxosmithkline inc · schedule Prescription
DIN 02238830: Clavulin (BID)
Raw flags: sec3=Y
Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id GSK
Source form: Susp; strength: 400mg & 57mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.3850; ministry $0.1591
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238830
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62268Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539446 · $0.1591
M-Amoxi Clav · DIN 02530694 · $0.1591
Shortage status: resolved shortage (ended March 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238830
Shortage record checked October 6, 2026
Jamp Amoxi Clav Suspension · DIN 02539446 · 400 mg & 57 mg/5 mL · suspension
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539446
Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27
Health Canada: Marketed since 2024-07-22 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML · company Jamp pharma corporation · schedule Prescription
Jamp Amoxi Clav Suspension: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1591). What the ministry pays, not the patient.
Ministry pays: $0.1591 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02539446: Jamp Amoxi Clav Suspension
Raw flags: sec3=Y
Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id JPC
Source form: Susp; strength: 400mg & 57mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.1591; ministry $0.1591
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539446
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102819Interchangeable products
Clavulin (BID) · DIN 02238830 · $0.1591
M-Amoxi Clav · DIN 02530694 · $0.1591
Shortage status: active shortage (reported June 30, 2026, estimated to end September 28, 2026, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539446
Shortage record checked October 6, 2026
M-Amoxi Clav · DIN 02530694 · 400 mg & 57 mg/5 mL · suspension
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amoxi Clav · DIN 02530694
Manufacturer: Mantra Pharma Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-24 · brand M-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML · company Mantra pharma inc · schedule Prescription
DIN 02530694: M-Amoxi Clav
Raw flags: sec3=Y
Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id MAT
Source form: Susp; strength: 400mg & 57mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.1591; ministry $0.1591
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02530694
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101985Interchangeable products
Clavulin (BID) · DIN 02238830 · $0.1591
Jamp Amoxi Clav Suspension · DIN 02539446 · $0.1591
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02530694
Amoxicillin/Clav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.
Ministry pays: $0.3778 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02536021: Amoxicillin/Clav
Raw flags: sec3=Y
Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id SAI
Source form: Tab; strength: 500mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.3778; ministry $0.3778
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536021
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102484Interchangeable products
Apo-Amoxi Clav · DIN 02243351 · $0.3778
Auro-Amoxiclav · DIN 02471698 · $0.3778
Clavulin · DIN 01916858 · not recorded
Jamp Amoxi Clav · DIN 02508257 · $0.3778
Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536021
Apo-Amoxi Clav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.
Ministry pays: $0.3778 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02243351: Apo-Amoxi Clav
Raw flags: sec3=Y
Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id APX
Source form: Tab; strength: 500mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.3778; ministry $0.3778
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243351
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67258Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778
Auro-Amoxiclav · DIN 02471698 · $0.3778
Clavulin · DIN 01916858 · not recorded
Jamp Amoxi Clav · DIN 02508257 · $0.3778
Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: resolved shortage (ended June 19, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243351
Auro-Amoxiclav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.
Ministry pays: $0.3778 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02471698: Auro-Amoxiclav
Raw flags: sec3=Y
Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id AUR
Source form: Tab; strength: 500mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.3778; ministry $0.3778
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471698
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96091Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778
Apo-Amoxi Clav · DIN 02243351 · $0.3778
Clavulin · DIN 01916858 · not recorded
Jamp Amoxi Clav · DIN 02508257 · $0.3778
Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: resolved shortage (ended February 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471698
Jamp Amoxi Clav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.
Ministry pays: $0.3778 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02508257: Jamp Amoxi Clav
Raw flags: sec3=Y
Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id JPC
Source form: Tab; strength: 500mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.3778; ministry $0.3778
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508257
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99764Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778
Apo-Amoxi Clav · DIN 02243351 · $0.3778
Auro-Amoxiclav · DIN 02471698 · $0.3778
Clavulin · DIN 01916858 · not recorded
Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508257
Sandoz Amoxi-Clav Tablets: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.
Ministry pays: $0.3778 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02482576: Sandoz Amoxi-Clav Tablets
Raw flags: sec3=Y
Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id SDZ
Source form: Tab; strength: 500mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.3778; ministry $0.3778
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482576
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97300Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778
Apo-Amoxi Clav · DIN 02243351 · $0.3778
Auro-Amoxiclav · DIN 02471698 · $0.3778
Clavulin · DIN 01916858 · not recorded
Jamp Amoxi Clav · DIN 02508257 · $0.3778
Shortage status: resolved shortage (ended January 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02482576
Amoxicillin/Clav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.
Ministry pays: $0.5551 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02536048: Amoxicillin/Clav
Raw flags: sec3=Y
Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id SAI
Source form: Tab; strength: 875mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.5551; ministry $0.5551
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536048
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102485Interchangeable products
Apo-Amoxi Clav · DIN 02245623 · $0.5551
Auro-Amoxiclav · DIN 02471701 · $0.5551
Clavulin (BID) · DIN 02238829 · not recorded
Jamp Amoxi Clav · DIN 02508265 · $0.5551
Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536048
Apo-Amoxi Clav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.
Ministry pays: $0.5551 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02245623: Apo-Amoxi Clav
Raw flags: sec3=Y
Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id APX
Source form: Tab; strength: 875mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.5551; ministry $0.5551
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245623
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69723Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551
Auro-Amoxiclav · DIN 02471701 · $0.5551
Clavulin (BID) · DIN 02238829 · not recorded
Jamp Amoxi Clav · DIN 02508265 · $0.5551
Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended April 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245623
Auro-Amoxiclav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.
Ministry pays: $0.5551 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02471701: Auro-Amoxiclav
Raw flags: sec3=Y
Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id AUR
Source form: Tab; strength: 875mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.5551; ministry $0.5551
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471701
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96092Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551
Apo-Amoxi Clav · DIN 02245623 · $0.5551
Clavulin (BID) · DIN 02238829 · not recorded
Jamp Amoxi Clav · DIN 02508265 · $0.5551
Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471701
Jamp Amoxi Clav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.
Ministry pays: $0.5551 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02508265: Jamp Amoxi Clav
Raw flags: sec3=Y
Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id JPC
Source form: Tab; strength: 875mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.5551; ministry $0.5551
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508265
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99765Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551
Apo-Amoxi Clav · DIN 02245623 · $0.5551
Auro-Amoxiclav · DIN 02471701 · $0.5551
Clavulin (BID) · DIN 02238829 · not recorded
Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended May 31, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508265
Sandoz Amoxi-Clav Tablets: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.
Ministry pays: $0.5551 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02482584: Sandoz Amoxi-Clav Tablets
Raw flags: sec3=Y
Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id SDZ
Source form: Tab; strength: 875mg & 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.5551; ministry $0.5551
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482584
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97301Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551
Apo-Amoxi Clav · DIN 02245623 · $0.5551
Auro-Amoxiclav · DIN 02471701 · $0.5551
Clavulin (BID) · DIN 02238829 · not recorded
Jamp Amoxi Clav · DIN 02508265 · $0.5551
Shortage status: resolved shortage (ended November 28, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02482584
Shortage record checked October 6, 2026
Jamp Amoxi Clav Suspension · DIN 02539411 · 200 mg & 28.5 mg/5 mL · suspension
Jamp Amoxi Clav Suspension: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.1007). What the ministry pays, not the patient.
Ministry pays: $0.1007 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02539411: Jamp Amoxi Clav Suspension
Raw flags: sec3=Y
Item: 081216081; group id 26; item number 0050; lccId None; manufacturer id JPC
Source form: Susp; strength: 200mg & 28.5mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.1007; ministry $0.1007
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539411
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102817Interchangeable products
Clavulin (BID) · DIN 02238831 · $0.1007
Shortage status: active shortage (reported December 23, 2024, estimated to end September 28, 2026, last updated September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539411
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.Discontinued August 2, 2007 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Clavulin · DIN 01916866
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01
Daily cost (source): $0.7401
Health Canada: Cancelled post market since 2007-08-02 · brand CLAVULIN 250 TAB · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Glaxosmithkline inc · schedule Prescription
DIN 01916866: Clavulin
Raw flags: notABenefit=Y, sec3=Y
Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id GSK
Source form: Tab; strength: 250mg & 125mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916866
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18891Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467
Auro-Amoxiclav · DIN 02471671 · $0.2467
Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01916866
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 2, 2007 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.Discontinued January 13, 2024 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Clavulin · DIN 01916858
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01
Daily cost (source): $1.1334
Health Canada: Cancelled post market since 2024-01-13 · brand CLAVULIN 500 F TAB · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Glaxosmithkline inc · schedule Prescription
DIN 01916858: Clavulin
Raw flags: notABenefit=Y, sec3=Y
Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id GSK
Source form: Tab; strength: 500mg & 125mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916858
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15903Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778
Apo-Amoxi Clav · DIN 02243351 · $0.3778
Auro-Amoxiclav · DIN 02471698 · $0.3778
Jamp Amoxi Clav · DIN 02508257 · $0.3778
Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: discontinued (January 31, 2024, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01916858
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 13, 2024 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (J01C, J01CR): coverage varies; not interchangeable
Piperacillin + tazobactam (Tazocin): not a benefit
Amoxicillin (Novamoxin): general benefit, not a benefit, listing status unconfirmed
Ampicillin (Penbritin): general benefit, not a benefit
Cloxacillin (Orbenin): general benefit, not a benefit
Penicillin v (Nadopen-V): general benefit, not a benefit
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered
Matched class: 08:12:16 Penicillins
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): AMOXICILLIN, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM)
08:12:16 Penicillins
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit
5 - Lower respiratory tract infections
PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10
Product monographCEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3)
• Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species,
Staph. aureus, Strep. pneumoniae and species (excluding enterococci).
PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications
CLAVULIN (amoxicillin / clavulanate potassium) is indicated for the treatment of the following
infections when caused by CLAVULIN-susceptible strains of the designated bacteria:
• Sinusitis when caused by β-lactamase producing strains of H. influenzae or Moraxella
(Branhamella) catarrhalis.
• Otitis Media when caused by β-lactamase producing strains of H. influenzae or Moraxella
(Branhamella) catarrhalis.
• Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae,
K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis.
• Skin and Soft Tissue Infections when caused by β-lactamase producing strains of S. aureus.
• Urinary Tract Infections when caused by β-lactamase producing strains of E. coli.
While CLAVULIN is indicated only for the conditions listed above, infections caused by ampicillin
(amoxicillin) susceptible organisms are also amenable to CLAVULIN treatment due to its amoxicillin
content. Furthermore, mixed infections caused by organisms susceptible to ampicillin (amoxicillin) and
β-lactamase producing organisms susceptible to CLAVULIN should not require the addition of another
an…
https://pdf.hres.ca/dpd_pm/00084428.PDF
PM date: 2026-04-24
Source product: CLAVULIN 250 F ORAL SUS; DIN 01916874; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Jamp Amoxi Clav Suspension · DIN 02539438
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-11-20, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539438
Apo-Amoxi Clav · DIN 02243350
Shortage status: shortage reported ended 2026-04-23 (report last updated 2026-04-23); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243350
Jamp Amoxi Clav Suspension · DIN 02539446
Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-09-28, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539446
Jamp Amoxi Clav Suspension · DIN 02539411
Shortage status: active shortage (reported 2024-12-23, estimated to end 2026-09-28, last updated 2026-09-22); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539411
Clavulin · DIN 01916858
Shortage status: discontinued (2024-01-31, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01916858
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Clavulin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.